Cribriform intraductal carcinoma of the prostate may be more aggressive than cribriform conventional/acinar prostatic adenocarcinoma
- PMID: 39592308
- DOI: 10.1016/j.pathol.2024.08.012
Cribriform intraductal carcinoma of the prostate may be more aggressive than cribriform conventional/acinar prostatic adenocarcinoma
Abstract
It remains to be determined if the prognostic value of cribriform morphology (Crib) associated with intraductal carcinoma of the prostate (IDC) is equivalent to that in conventional/acinar prostatic adenocarcinoma (CPA). We herein assessed radical prostatectomy findings and long-term oncologic outcomes in 732 men with Grade Group 2-4 CPA without any Gleason pattern 5. Our cases were divided into four cohorts according to the absence or presence of Crib within CPA and/or IDC: Cohort-1, no Crib (n=347; 47.4%); Cohort-2, Crib only in CPA (n=203; 27.7%); Cohort-3, Crib only in IDC (n=17; 2.3%); and Cohort-4, Crib in both CPA and IDC (n=165; 22.5%). Compared with that in CPA only (Cohort-2), Crib in both CPA and IDC (Cohort-4) was significantly associated with adverse histopathological features, including higher tumour grade/stage and larger tumour volume. Univariate analysis revealed significantly higher risks of postoperative recurrence in patients with Crib in IDC only [Cohort-3; hazard ratio (HR) 2.450, p=0.022] or both CPA and IDC (Cohort-4; HR 2.835, p<0.001) than in those with Crib in CPA only (Cohort-2), whereas the prognosis was analogous between Cohort-3 and Cohort-4 (p=0.913). In a multivariable analysis [Crib in CPA only (Cohort-2) as a reference], Crib in IDC only (Cohort-3; HR 3.821, p=0.002) or both CPA and IDC (Cohort-4; HR 1.905, p=0.004) showed significantly worse recurrence-free survival. Compared with Crib in CPA only, its presence in both CPA and IDC was thus found to be independently associated with a poorer prognosis, suggesting a potentially greater clinical impact of Crib in IDC than in CPA.
Keywords: biochemical recurrence; conventional/acinar prostatic adenocarcinoma; cribriform morphology; intraductal carcinoma of the prostate; prostate cancer; radical prostatectomy.
Copyright © 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding The authors state that there are no conflicts of interest to disclose. This work did not receive any specific grant from funding agencies in the public, commercial, or non-profit sectors.
Similar articles
-
Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable.Hum Pathol. 2023 Aug;138:112-120. doi: 10.1016/j.humpath.2023.06.011. Epub 2023 Jun 24. Hum Pathol. 2023. PMID: 37364826
-
Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.Eur J Cancer. 2014 Jun;50(9):1610-6. doi: 10.1016/j.ejca.2014.03.009. Epub 2014 Apr 3. Eur J Cancer. 2014. PMID: 24703897
-
Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes.Prostate Cancer Prostatic Dis. 2025 Mar;28(1):187-192. doi: 10.1038/s41391-024-00910-3. Epub 2024 Oct 21. Prostate Cancer Prostatic Dis. 2025. PMID: 39433886
-
Intraductal Carcinoma of the Prostate without High-Grade Invasive Adenocarcinoma: Report of Two Cases and Review of the Literature.Arch Esp Urol. 2022 Nov;75(9):738-745. doi: 10.56434/j.arch.esp.urol.20227509.108. Arch Esp Urol. 2022. PMID: 36472055 Review.
-
Intraductal Carcinoma of the Prostate Gland: Recent Advances.Yonsei Med J. 2016 Sep;57(5):1054-62. doi: 10.3349/ymj.2016.57.5.1054. Yonsei Med J. 2016. PMID: 27401634 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical